Company Description
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs.
Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss.
It operates in Switzerland, the United States, Europe, and Australia.
The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021.
Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
| Country | BM |
| IPO Date | Aug 6, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Dr. Thomas Meyer Ph.D. |
Contact Details
Address: Clarendon House Hamilton, BM | |
| Website | https://altamiratherapeutics.com |
Stock Details
| Ticker Symbol | CYTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001601936 |
| CUSIP Number | G0360L100 |
| ISIN Number | BMG0360L1349 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas Meyer Ph.D. | Founder, President, Chairman, Chief Executive Officer & MD |
| Dr. Covadonga Paneda | Chief Operating Officer |
| Marcel Gremaud CPA | Chief Financial Officer |
| Dr. Samuel A. Wickline M.D. | Chief Scientific Adviser |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 04, 2024 | 6-K | Filing |
| Sep 24, 2024 | 6-K | Filing |
| Sep 19, 2024 | 6-K | Filing |
| Sep 18, 2024 | 424B4 | Filing |
| Sep 16, 2024 | F-1/A | [Amend] Filing |
| Sep 16, 2024 | F-1/A | [Amend] Filing |
| Aug 22, 2024 | F-1 | Filing |
| Jul 08, 2024 | POS AM | Filing |
| Jul 01, 2024 | 20-F/A | [Amend] Filing |